Lilly’s new Alzheimer’s drug could generate $7.1B in sales: analyst (NYSE:LLY)
2024-07-03
jetcityimage/iStock Editorial via Getty Images Eli Lilly’s (NYSE:LLY) newly approved Alzheimer’s drug Kisunla could generate peak sales of up to $7.1B for the company and will help diversify the drugmaker’s revenue stream, according to BMO. Kisunla, also known as donanemab, will be priced at $32,000 per year, with each vialContinue Reading